Gastrointestinal stromal tumors express ras oncogene: A potential role for diagnosis and treatment

Archives of Surgery

Volumn 140, Issue 6, 2005, Pages 543-548

  Blair, Sarah L ^a,e   Al Refaie, Waddah B ^c   Wang Rodriguez, Jessica ^b   Behling, Cynthia ^b   Ali, Mir Wasif ^a   Moossa, A R ^a   Bilchik, Anton ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d NONE

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ONCOGENE RAS; PHOSPHORYLATION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SPINDLE CELL; TREATMENT OUTCOME; ARTICLE; GENETICS; LEIOMYOBLASTOMA; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; TUMOR RECURRENCE;

PROTEIN P21; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOMA, EPITHELIOID; LEIOMYOSARCOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEIN P21(RAS); PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES;

EID: 21244474094     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.140.6.543     Document Type: Review

References (15)

1. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38(suppl 5):S39-S51.
2. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg. 2003;90:332-339.
3. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001;136:383-389.
4. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001;8:50-59.
5. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol. 2001;8:290-299.
6. Gu M, Ghafari S, Nguyen PT, Lin F. Cytologic diagnosis of gastrointestinal stromal tumors of the stomach by endoscopic ultrasound-guided fine-needle aspiration biopsy: cytomorphologic and immunohistochemical study of 12 cases. Diagn Cytopathol. 2001;25:343-350.
7. Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43:118-126.
8. Panizo-Santos A, Sola I, Vega F, et al. Predicting metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol. 2000;8:133-144.
9. Al-Bozom IA. p53 expression in gastrointestinal stromal tumors. Pathol Int. 2001;51:519-523.
10. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res. 2003;9:3329-3337.
11. Duronio V, Welham MJ, Abraham S, Dryden P, Schrader JW. p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein. Proc Natl Acad Sci U S A. 1992;89:1587-1591.
12. Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene. 1999;18:5546-5553.
13. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D. Immunophenotype, proliferation, DNA ploidy and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol. 1998;29:791-800.
14. Sawyers CL. Cancer treatment in the STI571 era: what will change? J Clin Oncol. 2001;19(suppl 18):13S-16S.
15. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J. 2004;5:55-60.